# Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

> **NCT00047307** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** alvocidib
- **DRUG:** gemcitabine hydrochloride
- **RADIATION:** 3-dimensional conformal radiation therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00047307
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047307, "Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00047307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*